| Literature DB >> 30075130 |
Li Li1, E Tian2, Xianwei Chen2, Jianfei Chao2, Jeremy Klein2, Qiuhao Qu2, Guihua Sun3, Guoqiang Sun2, Yanzhou Huang2, Charles D Warden4, Peng Ye2, Lizhao Feng2, Xinqiang Li2, Qi Cui2, Abdullah Sultan2, Panagiotis Douvaras5, Valentina Fossati5, Neville E Sanjana6, Arthur D Riggs3, Yanhong Shi7.
Abstract
Alexander disease (AxD) is a leukodystrophy that primarily affects astrocytes and is caused by mutations in the astrocytic filament gene GFAP. While astrocytes are thought to have important roles in controlling myelination, AxD animal models do not recapitulate critical myelination phenotypes and it is therefore not clear how AxD astrocytes contribute to leukodystrophy. Here, we show that AxD patient iPSC-derived astrocytes recapitulate key features of AxD pathology such as GFAP aggregation. Moreover, AxD astrocytes inhibit proliferation of human iPSC-derived oligodendrocyte progenitor cells (OPCs) in co-culture and reduce their myelination potential. CRISPR/Cas9-based correction of GFAP mutations reversed these phenotypes. Transcriptomic analyses of AxD astrocytes and postmortem brains identified CHI3L1 as a key mediator of AxD astrocyte-induced inhibition of OPC activity. Thus, this iPSC-based model of AxD not only recapitulates patient phenotypes not observed in animal models, but also reveals mechanisms underlying disease pathology and provides a platform for assessing therapeutic interventions.Entities:
Keywords: Alexander disease; CHI3L1; astrocytes; disease modeling; iPSCs; leukodystrophy; myelination; neurological disease; oligodendrocyte progenitor cells; oligodendrocytes
Mesh:
Substances:
Year: 2018 PMID: 30075130 PMCID: PMC6230521 DOI: 10.1016/j.stem.2018.07.009
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633